Peptide record

TPDB09218

Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity standard
19 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB09218
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia Antifungipept CAFPdb APD_complete Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 19-aa standard-residue multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
FLWGLIPGAISAVTSLIKK
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C98H160N22O23
RNDCEQHMY
IL
2014.48
10.60
2
0
11
+2
-1.26
1.163
148.95
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
5500
2.73
3
Residue Composition
number
2
A
0
R
0
N
0
D
0
C
0
E
0
Q
2
G
0
H
3
I
3
L
2
K
0
M
1
F
1
P
2
S
1
T
1
W
0
Y
1
V
Amino Acid Distribution
A: 2 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 3 L: 3 K: 2 M: 0 F: 1 P: 1 S: 2 T: 1 W: 1 Y: 0 V: 1
Chemical Descriptors
19 reviewed residue count
C98H160N22O23 sequence-only estimate (linear, free termini)
2014.48 sequence-only estimate (linear, free termini)
10.60 sequence-only estimate (linear, free termini)
+2 sequence-only estimate (linear, free termini)
-1.26 sequence-only estimate (linear, free termini)
1.163 sequence-only estimate (linear, free termini)
Evidence Records 31 records
Evidence 1 Activity

Activity

MIC
Antibacterial
5-32 µg/mL

Target

Staphylococcus aureus AB94004 MRSA

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Active against S. aureus AB94004 MRSA (MIC 5-32 ug/ml), B. thuringiensis AB92037 (MIC 10 ug/ml), B. subtilis AB91021 (MIC 10 ug/ml), M. luteus A
Evidence 2 Activity

Activity

MIC
Antibacterial
10 µg/mL

Target

B. thuringiensis AB92037

Source & Reference

dbAMP DRAMP

Other

Active against S. aureus AB94004 MRSA (MIC 5-32 ug/ml), B. thuringiensis AB92037 (MIC 10 ug/ml), B. subtilis AB91021 (MIC 10 ug/ml), M. luteus AB93113 (MIC 5 ug/ml), and C. albicans AY9
Evidence 3 Activity

Activity

MIC
Antibacterial
10 µg/mL

Target

B. subtilis AB91021

Source & Reference

dbAMP DRAMP

Other

against S. aureus AB94004 MRSA (MIC 5-32 ug/ml), B. thuringiensis AB92037 (MIC 10 ug/ml), B. subtilis AB91021 (MIC 10 ug/ml), M. luteus AB93113 (MIC 5 ug/ml), and C. albicans AY93025 (MIC 20 ug/ml). In particular,
Evidence 4 Activity

Activity

MIC
Antibacterial
5 µg/mL

Target

M. luteus AB93113

Source & Reference

dbAMP DRAMP

Other

5-32 ug/ml), B. thuringiensis AB92037 (MIC 10 ug/ml), B. subtilis AB91021 (MIC 10 ug/ml), M. luteus AB93113 (MIC 5 ug/ml), and C. albicans AY93025 (MIC 20 ug/ml). In particular, it is active against clinical iso
Evidence 5 Activity

Activity

MIC
Antibacterial
20 µg/mL

Target

Candida albicans AY93025

Source & Reference

dbAMP DRAMP

Other

(MIC 10 ug/ml), B. subtilis AB91021 (MIC 10 ug/ml), M. luteus AB93113 (MIC 5 ug/ml), and C. albicans AY93025 (MIC 20 ug/ml). In particular, it is active against clinical isolates MRSA, penicillin-resistant S. epid
Evidence 6 Activity

Activity

MIC
Antibacterial
64 µg/mL

Target

E. faecium ATCC29212

Source & Reference

dbAMP DRAMP

Other

t clinical isolates MRSA, penicillin-resistant S. epidermidis at 10 ug/ml. active against E. faecium ATCC29212 (MIC 64 ug/ml), A. baumannii ATCC19606 (MIC 16 ug/ml). However, the peptide is inactive against E.coli o
Evidence 7 Activity

Activity

MIC
Antibacterial
16 µg/mL

Target

A. baumannii ATCC19606

Source & Reference

dbAMP DRAMP

Other

resistant S. epidermidis at 10 ug/ml. active against E. faecium ATCC29212 (MIC 64 ug/ml), A. baumannii ATCC19606 (MIC 16 ug/ml). However, the peptide is inactive against E.coli or P.aeruginosa (>100 ug/ml).
Evidence 8 Activity

Activity

MIC
Antifungal
5-32 µg/mL

Target

Staphylococcus aureus AB94004 MRSA

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Active against S. aureus AB94004 MRSA (MIC 5-32 ug/ml), B. thuringiensis AB92037 (MIC 10 ug/ml), B. subtilis AB91021 (MIC 10 ug/ml), M. luteus A
Evidence 9 Activity

Activity

MIC
Antifungal
10 µg/mL

Target

B. thuringiensis AB92037

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Active against S. aureus AB94004 MRSA (MIC 5-32 ug/ml), B. thuringiensis AB92037 (MIC 10 ug/ml), B. subtilis AB91021 (MIC 10 ug/ml), M. luteus AB93113 (MIC 5 ug/ml), and C. albicans AY9
Evidence 10 Activity

Activity

MIC
Antifungal
10 µg/mL

Target

B. subtilis AB91021

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

against S. aureus AB94004 MRSA (MIC 5-32 ug/ml), B. thuringiensis AB92037 (MIC 10 ug/ml), B. subtilis AB91021 (MIC 10 ug/ml), M. luteus AB93113 (MIC 5 ug/ml), and C. albicans AY93025 (MIC 20 ug/ml). In particular,
Evidence 11 Activity

Activity

MIC
Antifungal
5 µg/mL

Target

M. luteus AB93113

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

5-32 ug/ml), B. thuringiensis AB92037 (MIC 10 ug/ml), B. subtilis AB91021 (MIC 10 ug/ml), M. luteus AB93113 (MIC 5 ug/ml), and C. albicans AY93025 (MIC 20 ug/ml). In particular, it is active against clinical iso
Evidence 12 Activity

Activity

MIC
Antifungal
20 µg/mL

Target

Candida albicans AY93025

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

(MIC 10 ug/ml), B. subtilis AB91021 (MIC 10 ug/ml), M. luteus AB93113 (MIC 5 ug/ml), and C. albicans AY93025 (MIC 20 ug/ml). In particular, it is active against clinical isolates MRSA, penicillin-resistant S. epid
Evidence 13 Activity

Activity

MIC
Antifungal
64 µg/mL

Target

E. faecium ATCC29212

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

t clinical isolates MRSA, penicillin-resistant S. epidermidis at 10 ug/ml. active against E. faecium ATCC29212 (MIC 64 ug/ml), A. baumannii ATCC19606 (MIC 16 ug/ml). However, the peptide is inactive against E.coli o
Evidence 14 Activity

Activity

MIC
Antifungal
16 µg/mL

Target

A. baumannii ATCC19606

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

resistant S. epidermidis at 10 ug/ml. active against E. faecium ATCC29212 (MIC 64 ug/ml), A. baumannii ATCC19606 (MIC 16 ug/ml). However, the peptide is inactive against E.coli or P.aeruginosa (>100 ug/ml).
Evidence 15 Activity

Activity

MIC
Antiparasitic
5-32 µg/mL

Target

Staphylococcus aureus AB94004 MRSA

Source & Reference

DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets.
Active against S. aureus AB94004 MRSA (MIC 5-32 ug/ml), B. thuringiensis AB92037 (MIC 10 ug/ml), B. subtilis AB91021 (MIC 10 ug/ml), M. luteus A
Evidence 16 Activity

Activity

MIC
Antiparasitic
10 µg/mL

Target

B. thuringiensis AB92037

Source & Reference

DRAMP

Other

Active against S. aureus AB94004 MRSA (MIC 5-32 ug/ml), B. thuringiensis AB92037 (MIC 10 ug/ml), B. subtilis AB91021 (MIC 10 ug/ml), M. luteus AB93113 (MIC 5 ug/ml), and C. albicans AY9
Evidence 17 Activity

Activity

MIC
Antiparasitic
10 µg/mL

Target

B. subtilis AB91021

Source & Reference

DRAMP

Other

against S. aureus AB94004 MRSA (MIC 5-32 ug/ml), B. thuringiensis AB92037 (MIC 10 ug/ml), B. subtilis AB91021 (MIC 10 ug/ml), M. luteus AB93113 (MIC 5 ug/ml), and C. albicans AY93025 (MIC 20 ug/ml). In particular,
Evidence 18 Activity

Activity

MIC
Antiparasitic
5 µg/mL

Target

M. luteus AB93113

Source & Reference

DRAMP

Other

5-32 ug/ml), B. thuringiensis AB92037 (MIC 10 ug/ml), B. subtilis AB91021 (MIC 10 ug/ml), M. luteus AB93113 (MIC 5 ug/ml), and C. albicans AY93025 (MIC 20 ug/ml). In particular, it is active against clinical iso
Evidence 19 Activity

Activity

MIC
Antiparasitic
20 µg/mL

Target

Candida albicans AY93025

Source & Reference

DRAMP

Other

(MIC 10 ug/ml), B. subtilis AB91021 (MIC 10 ug/ml), M. luteus AB93113 (MIC 5 ug/ml), and C. albicans AY93025 (MIC 20 ug/ml). In particular, it is active against clinical isolates MRSA, penicillin-resistant S. epid
Evidence 20 Activity

Activity

MIC
Antiparasitic
64 µg/mL

Target

E. faecium ATCC29212

Source & Reference

DRAMP

Other

t clinical isolates MRSA, penicillin-resistant S. epidermidis at 10 ug/ml. active against E. faecium ATCC29212 (MIC 64 ug/ml), A. baumannii ATCC19606 (MIC 16 ug/ml). However, the peptide is inactive against E.coli o
Evidence 21 Activity

Activity

MIC
Antiparasitic
16 µg/mL

Target

A. baumannii ATCC19606

Source & Reference

DRAMP

Other

resistant S. epidermidis at 10 ug/ml. active against E. faecium ATCC29212 (MIC 64 ug/ml), A. baumannii ATCC19606 (MIC 16 ug/ml). However, the peptide is inactive against E.coli or P.aeruginosa (>100 ug/ml).
Evidence 22 Activity

Activity

MIC
Antiviral
5-32 µg/mL

Target

Staphylococcus aureus AB94004 MRSA

Source & Reference

DRAMP

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets.
Active against S. aureus AB94004 MRSA (MIC 5-32 ug/ml), B. thuringiensis AB92037 (MIC 10 ug/ml), B. subtilis AB91021 (MIC 10 ug/ml), M. luteus A
Evidence 23 Activity

Activity

MIC
Antiviral
10 µg/mL

Target

B. thuringiensis AB92037

Source & Reference

DRAMP

Other

Active against S. aureus AB94004 MRSA (MIC 5-32 ug/ml), B. thuringiensis AB92037 (MIC 10 ug/ml), B. subtilis AB91021 (MIC 10 ug/ml), M. luteus AB93113 (MIC 5 ug/ml), and C. albicans AY9
Evidence 24 Activity

Activity

MIC
Antiviral
10 µg/mL

Target

B. subtilis AB91021

Source & Reference

DRAMP

Other

against S. aureus AB94004 MRSA (MIC 5-32 ug/ml), B. thuringiensis AB92037 (MIC 10 ug/ml), B. subtilis AB91021 (MIC 10 ug/ml), M. luteus AB93113 (MIC 5 ug/ml), and C. albicans AY93025 (MIC 20 ug/ml). In particular,
Evidence 25 Activity

Activity

MIC
Antiviral
5 µg/mL

Target

M. luteus AB93113

Source & Reference

DRAMP

Other

5-32 ug/ml), B. thuringiensis AB92037 (MIC 10 ug/ml), B. subtilis AB91021 (MIC 10 ug/ml), M. luteus AB93113 (MIC 5 ug/ml), and C. albicans AY93025 (MIC 20 ug/ml). In particular, it is active against clinical iso
Evidence 26 Activity

Activity

MIC
Antiviral
20 µg/mL

Target

Candida albicans AY93025

Source & Reference

DRAMP

Other

(MIC 10 ug/ml), B. subtilis AB91021 (MIC 10 ug/ml), M. luteus AB93113 (MIC 5 ug/ml), and C. albicans AY93025 (MIC 20 ug/ml). In particular, it is active against clinical isolates MRSA, penicillin-resistant S. epid
Evidence 27 Activity

Activity

MIC
Antiviral
64 µg/mL

Target

E. faecium ATCC29212

Source & Reference

DRAMP

Other

t clinical isolates MRSA, penicillin-resistant S. epidermidis at 10 ug/ml. active against E. faecium ATCC29212 (MIC 64 ug/ml), A. baumannii ATCC19606 (MIC 16 ug/ml). However, the peptide is inactive against E.coli o
Evidence 28 Activity

Activity

MIC
Antiviral
16 µg/mL

Target

A. baumannii ATCC19606

Source & Reference

DRAMP

Other

resistant S. epidermidis at 10 ug/ml. active against E. faecium ATCC29212 (MIC 64 ug/ml), A. baumannii ATCC19606 (MIC 16 ug/ml). However, the peptide is inactive against E.coli or P.aeruginosa (>100 ug/ml).
Evidence 29 Activity

Activity

10% Hemolysis
Toxicity
30 µg/mL
Hemolytic Cytotoxic
10% Hemolysis | 30 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Identification of the scorpion venom-derived antimicrobial peptide Hp1404 as a new antimicrobial agent against carbapenem-resistant Acinetobacter baumannii. | Microb Pathog | 2021
Evidence 30 Activity

Activity

90.6±11.8% Hemolysis
Toxicity
256 µg/mL
Hemolytic Cytotoxic
90.6±11.8% Hemolysis | 256 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Cationicity Enhancement on the Hydrophilic Face of Ctriporin Significantly Reduces Its Hemolytic Activity and Improves the Antimicrobial Activity against Antibiotic-Resistant ESKAPE Pathogens. | Toxins (Basel) | 2024
Evidence 31 Hemolysis

Source & Reference

APD_complete PD_Hemolysis
APD_complete PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation.